Clinical trials: Depressive Disorder NOS
Depressive Disorder, Major
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)
This study will evaluate the efficacy, safety, and tolerability of two doses of rapastinel, 225 milligrams (mg) and 450 mg, compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder…
- Trial name
- NCT02943564
- Testing
- Rapastinel
- Where
- 66 sites in United States
- Volunteers
- 658 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder
The objective of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran compared with placebo in pediatric outpatients (7-17 years) with major depressive disorder (MDD).
- Trial name
- NCT03569475
- Testing
- Levomilnacipran ER, Fluoxetine
- Where
- 51 sites in United States
- Volunteers
- 501 people
- Sponsor
- Allergan
Depressive Disorder
TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of TAK-653 when administered as single and multiple oral doses at escalating dose levels in healthy participants.
- Trial name
- NCT02561156
- Testing
- TAK-653
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04533529
- Testing
- Seltorexant
- Where
- 122 sites in United States, Brazil and 9 more
- Volunteers
- 588 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Effects of Amygdala Neurofeedback on Depressive Symptoms
The purpose of this study is to determine the clinical efficacy of augmenting cognitive-behavioral therapy with real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) training to increase the amygdala's…
- Trial name
- NCT02709161
- Testing
- real-time fMRI neurofeedback: Amygdala, real-time fMRI neurofeedback: HIPS
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Kymberly Young
Depressive Disorder, Parkinson Disease
Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease
This study will evaluate the effectiveness of atomoxetine in reducing symptoms of depression in people with Parkinson's disease.
- Trial name
- NCT00304161
- Testing
- Atomoxetine
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Pennsylvania
Posttraumatic Stress Disorder, Major Depressive Disorder
Predicting SSRI Efficacy in Veterans With PTSD
This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective…
- Trial name
- SSRI (NCT04183205)
- Testing
- LDAEP, sertraline
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Home-based tDCS in Major Depressive Disorder
The investigators propose a study of telehealth supervised, caregiver-delivered, home-based transcranial direct current stimulation (tDCS) for antidepressant treatment of patients with an acute depressive episode.
- Trial name
- MoodStim (NCT04799405)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Hebrew SeniorLife
Schizophrenia, Schizoaffective Disorder
Lifestyle Intervention for Young Adults With Serious Mental Illness
This is a four year project evaluating the effectiveness of a group-based lifestyle intervention (PeerFIT) supported by mobile health (mHealth) technology and social media compared to Basic Education in fitness and nutrition…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT02815813
- Testing
- PeerFIT, BEAT
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Major Depression
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
Background: Drugs and talk therapy help treat depression, but these treatments usually take quite a bit of time to work. Ketamine is a fast-acting antidepressant, but it has side effects like unusual dreams and experiences.
- Trial name
- NCT02484456
- Testing
- AV 101 (4-Chlorokynurenine)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depression, End Stage Renal Disease
A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}
Patients whose kidneys fail generally require dialysis treatments to sustain life. The ability of patients to make major adjustments in their lives for dialysis is hampered by depression that affects almost one-quarter of such…
- Trial name
- ASCEND (NCT02358343)
- Testing
- Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy
- Where
- 3 sites in United States
- Volunteers
- 184 people
- Sponsor
- University of Washington
Major Depressive Disorder
Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)
The purpose of this study is to see if using Cranial Electrical Stimulation (CES) helps improve symptoms of major depressive disorder (MDD).
- Trial name
- NCT01325532
- Testing
- Active CES
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major
Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression
The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.
- Trial name
- NCT00186498
- Testing
- memantine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Major Depressive Disorder, MDD
Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder
The primary purpose of this study is to test the safety and feasibility of virtual reality (VR) technology in the use of behavioral activation (BA) as a treatment for major depressive disorder (MDD).
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT04268316
- Testing
- Virtual Reality Behavioral Activation, Behavioral Activation in real-life
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Major Depressive Disorder
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.
- Trial name
- NCT00735709
- Testing
- Vortioxetine
- Where
- 48 sites in Australia, Czechia and 13 more
- Volunteers
- 560 people
- Sponsor
- Takeda
Major Depressive Disorder
Brain GABA Levels and Treatment Response in Major Depressive Disorder
This study will evaluate changes in brain gamma-aminobutyric acid (GABA) levels due to treatment with escitalopram in people with major depressive disorder.
- Trial name
- NCT00464711
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Panic Disorder, Major Depressive Disorder
Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression
This study will evaluate the efficacy of 1-Hz rTMS applied to the right Dorsolateral Prefrontal Cortex (DLPFC) in patients with Panic Disorder (PD) and comorbid Major Depressive Disorder (MDD) who have not fully responded to…
- Trial name
- rTMS (NCT00521352)
- Testing
- Active Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
The Effectiveness of rTMS in Depressed VA Patients
The purpose of this multi-site trial is to determine if repetitive Transcranial Magnetic Stimulation (rTMS) helps people with depression who have not been helped by medications or who have not been helped enough by medications.
- Trial name
- NCT01191333
- Testing
- rTMS
- Where
- 9 sites in United States
- Volunteers
- 164 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
Electroconvulsive therapy (ECT), is considered the most effective treatment for severe treatment resistant major depressive disorder (MDD), but it requires about 3 weeks of treatments and can cause considerable acute deficits in…
- Trial name
- NCT01260649
- Testing
- ketamine, IV Saline, ECT
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital